To the full analysis
Buyback calculator for Shanghai Allist Pharmaceuticals
Shanghai Allist Pharmaceuticals stock: key metrics
688578.SSShanghai Allist Pharmaceuticals had an operating margin of 49.8% and a return on invested capital (ROIC) of 81.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2017 | 96.9% | −502.1% | −503.9% |
| 2018 | 94.6% | −2,126.9% | −2,108.1% |
| 2019 | 57.1% | −60,548.0% | −63,123.4% |
| 2020 | 71.2% | −55,350.1% | −55,361.4% |
| 2021 | 94.3% | 4.1% | 3.4% |
| 2022 | 94.0% | 16.2% | 16.5% |
| 2023 | 94.5% | 32.6% | 31.9% |
| 2024 | 95.3% | 45.9% | 40.2% |
| 2025 | 96.8% | 49.8% | 42.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2017 | −10.2% | −8.0% | −7.7% |
| 2018 | −100.0% | −34.5% | −26.0% |
| 2019 | −33.6% | −40.4% | −29.9% |
| 2020 | −10.8% | −75.9% | −10.4% |
| 2021 | 0.6% | 4.2% | 0.6% |
| 2022 | 4.1% | 13.5% | 3.8% |
| 2023 | 16.2% | 45.2% | 14.7% |
| 2024 | 27.1% | 79.4% | 24.2% |
| 2025 | 30.8% | 81.1% | 27.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.